Oncology

With a seasoned CEO and a tech transformation guru joining its board, San Diego's Curebound signals a strategic shift to fast-track cancer cures.

A landmark accreditation for a community clinic is dismantling the barriers to CAR T-cell therapy, signaling a radical shift from elite centers to local care.

Beyond the pink ribbons, the CIBC Run for the Cure is a funding powerhouse. We unpack the 30-year alliance that's fueling AI-driven diagnostics and policy battles.

As it launches a pivotal trial for its MYC inhibitor, Persevere Therapeutics adds a seasoned CEO to its board, signaling a sharp focus on funding and strategy.

BioLineRx secures crucial funds for its cancer drugs, but at a cost. We dissect the deal, the shareholder dilution, and what it reveals about biotech financing.

As precision medicine generates a deluge of data, Iylon Oncology's appointment of Dr. Mary Lopresti shows the real value is not in the algorithm, but in human expertise.

A new FDA approval for Roche's HER2 tests paves the way for a powerful new drug, offering hope to patients with aggressive gastroesophageal adenocarcinoma.

With zero recurrences in a pivotal trial, a novel immunotherapy combination is rewriting the rules for early-stage colon cancer, targeting tumors once thought untouchable.

Allegheny Health Network and START's new partnership isn't just a local win; it's a blueprint for a more accessible, patient-centric future in oncology.

Avenzo Therapeutics' new CHRO hire is more than a personnel move; it's a critical piece of a master plan for a public debut and oncology market disruption.

A new trial for refractory melanoma relies on a breakthrough manufacturing platform from NTx Bio. This is how automation is making personalized vaccines a reality.

For glioblastoma patients, the wait for radiation is a race against time. A new device implanted during surgery is showing it can win that race.

PMV Pharma's rezatapopt shows remarkable results for a tough cancer by reactivating a key defense. A deep dive into the science, finances, and patient hope.

With a novel drug platform and new funding, Akari Therapeutics aims to redefine cancer therapy. But can its groundbreaking science outpace a ticking financial clock?

Kyntra Bio's Q2 profit was driven by a one-time accounting gain, masking operating losses. Now, the firm bets its future on two critical Q4 data readouts.

With a cash runway to 2029 and a novel cancer drug nearing key data, NuCana signals quiet confidence in a high-stakes race to treat resistant melanoma.

A San Diego biotech is advancing a device to clean the blood of disease-fueling particles. With early promise in cancer and a new path in Long COVID, can it navigate the financial realities of innovation?

Inhibrx Biosciences lands a massive new loan to fuel its promising cancer drug trials, but rising costs and a wider net loss paint a high-stakes picture.

Rigel's VEPPANU is the first FDA-approved PROTAC, a new class of drug that destroys disease proteins. This is the story behind the science and the numbers.

After securing a $114M financing deal, Pyxis Oncology has extended its runway into 2027, putting all focus on upcoming MICVO data for head and neck cancer.